Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3018]

Addition of blinatumomab to mini-hyper-CVD and inotuzumab improves outcomes in...

Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA

Addition of blinatumomab to mini-hyper-CVD and inotuzumab improves outcomes in R/R ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )

Ponatinib superior to imatinib in combination with reduced-intensity...

Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA

Ponatinib superior to imatinib in combination with reduced-intensity chemotherapy in newly diagnosed Ph positive ALL ( Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA )

Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone...

Prof Meletios Dimopoulos - National and Kapodistrian University of Athens...

$Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma ( Prof Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens, Greece )$

Belamaf monotherapy induced rapid responses without unexpected toxicity in...

Dr Efstathios Kastritis - National and Kapodistrian University of Athens...

$Belamaf monotherapy induced rapid responses without unexpected toxicity in relapsed or refractory light chain amyloidosis ( Dr Efstathios Kastritis - National and Kapodistrian University of Athens, Athens, Greece )$

Triplets for newly diagnosed unfit AML patients could be feasible with...

Dr Juan Miguel Bergua Burgues - Hospital San Pedro de Alcántara, Cáceres, Spain

Triplets for newly diagnosed unfit AML patients could be feasible with substantial venetoclax reduction ( Dr Juan Miguel Bergua Burgues - Hospital San Pedro de Alcántara, Cáceres, Spain )

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic...

Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City...

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer ( Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA )

The parotid gland; an unusual site of colorectal cancer metastasis

Dr Paula Isabel Franco - St Luke’s Medical Center, Malina, Philippines

The parotid gland; an unusual site of colorectal cancer metastasis ( Dr Paula Isabel Franco - St Luke’s Medical Center, Malina, Philippines )

ASCO's efforts to improve global cancer care through the years

Dr Carlos Santiago Vallejos Sologuren - Oncosalud, Lima, Peru

ASCO's efforts to improve global cancer care through the years ( Dr Carlos Santiago Vallejos Sologuren - Oncosalud, Lima, Peru )

US NCI's global health initiatives at ASCO 2023

Dr Satish Gopal - National Cancer Institute, Bethesda, USA

US NCI's global health initiatives at ASCO 2023 ( Dr Satish Gopal - National Cancer Institute, Bethesda, USA )

Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine...

Dr Lin-Quan Tang - Sun Yat-sen University, Guangzhou, China

Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine improves PFS in N2-3 nasopharyngeal carcinoma ( Dr Lin-Quan Tang - Sun Yat-sen University, Guangzhou, China )

Talazoparib plus enzalutamide shows improvement in PFS over standard of care in...

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

Talazoparib plus enzalutamide shows improvement in PFS over standard of care in firstline HRR mCRPC ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )

CDK4/6 inhibitors added to first line show no greater benefit when compared to...

Dr Gabe Sonke - Netherlands Cancer Institute, Amsterdam, Netherlands

CDK4/6 inhibitors added to first line show no greater benefit when compared to their use in second line therapy in HR+, HER2- ABC ( Dr Gabe Sonke - Netherlands Cancer Institute, Amsterdam, Netherlands )

More from ecancer